Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP083
MIFTS: 53

Hypopituitarism

Categories: Cardiovascular diseases, Endocrine diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Hypopituitarism

About this section

MalaCards integrated aliases for Hypopituitarism:

Name: Hypopituitarism 12 74 52 36 54 43 15 17 71 32
Pituitary Insufficiency 12 52
Pituitary Hormone Deficiency 12
Pituitary Hypofunction 12

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Endocrine diseases Neuronal diseases Cardiovascular diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:9406
KEGG 36 H01700
MeSH 43 D007018
NCIt 49 C62591
SNOMED-CT 67 74728003
ICD10 32 E23 E23.0
UMLS 71 C0020635
Sources

Summaries for Hypopituitarism

About this section
KEGG : 36 Hypopituitarism is a chronic endocrine illness, and is the partial or complete insufficiency of anterior pituitary hormone secretion. Anterior pituitary is composed of five cell types that secrete growth hormone (GH), prolactin (PRL), follicle-stimulating hormone (FSH) and luteinizing hormone (LH), thyroid stimulating hormone (TSH) and corticotropin hormone (ACTH). Clinical manifestations of hypopituitarism are variable, often insidious in onset and dependent on the degree and severity of hormone deficiency. However, it is associated with increased mortality and morbidity. A variety of diseases may cause hypopituitarism and, accordingly, this disorder can be divided into two types depending on its cause. Primary hypopituitarism is caused by disorders of the pituitary gland itself and may be due to the loss, damage, or dysfunction of pituitary hormone-secreting cells. On the other hand, secondary hypopituitarism is the result of diseases of the hypothalamus or pituitary stalk interrupting the nerve or vascular connections to the pituitary gland, thereby reducing the secretion of the pituitary hormones. Hypopituitarism can be easily diagnosed by measuring basal pituitary and target hormone levels. MR imaging of the hypothalamo-pituitary region may provide essential information. The most common causes of primary hypopituitarism are pituitary adenoma and complications from surgery or radiation therapy for the treatment of pituitary adenoma. In rare cases, hypopituitarism has been observed when the infection occurs. Sheehan's syndrome is hypopituitarism caused by the postpartum hemorrhage of the pituitary gland. In still rarer cases, solitary or complicated pituitary hormone deficiency syndromes may occur due to genetic causes and typically affect children. The treatment of hypopituitarism typically involves a replacement of the deficient hormone but care must be taken because several studies have reported an increased incidence of cardiovascular disorders and number of deaths among these patients.

MalaCards based summary : Hypopituitarism, also known as pituitary insufficiency, is related to congenital hypopituitarism and sheehan syndrome. An important gene associated with Hypopituitarism is PROP1 (PROP Paired-Like Homeobox 1), and among its related pathways/superpathways are Neuroactive ligand-receptor interaction and Peptide ligand-binding receptors. The drugs Testosterone and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and thyroid, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A pituitary gland disease characterized by the decreased secretion of one or more of the eight hormones normally produced by the pituitary gland.

NIH Rare Diseases : 52 Hypopituitarism occurs when the body has low levels of certain hormones made by the pituitary gland . The pituitary gland normally makes several hormones (including growth hormone, thyroid stimulating hormone, adrenocorticotropic hormone, prolactin, follicle stimulating hormone and luteinizing hormone, vasopressin, and oxytocin). These hormones are important for directing body growth and development, and for regulating blood pressure and metabolism. Symptoms of this condition vary and depend on which hormones are affected. Treatment depends on the cause of this condition; once the cause is corrected, medication (hormone replacement therapy) must be taken to provide the body with the normal amount of hormones.

Wikipedia : 74 Hypopituitarism is the decreased (hypo) secretion of one or more of the eight hormones normally produced... more...

Sources

Related Diseases for Hypopituitarism

About this section

Diseases in the Hypopituitarism family:

Congenital Hypopituitarism

Diseases related to Hypopituitarism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 835)
# Related Disease Score Top Affiliating Genes
1 congenital hypopituitarism 34.8 PROP1 LHX4 HESX1 GLI2 GHRH
2 sheehan syndrome 33.8 PROP1 PRL POMC INS IGF1 CRH
3 combined pituitary hormone deficiencies, genetic forms 33.4 PROP1 POU1F1 LHX4 HESX1 GLI2
4 lymphocytic hypophysitis 33.2 POMC GH1
5 isolated growth hormone deficiency 32.5 SOX3 PROP1 POU1F1 POMC LHX4 LHX3
6 pituitary hormone deficiency, combined, 2 32.3 TRH SOX3 PROP1 PRL POU1F1 POMC
7 hypothalamic disease 32.1 TRH PRL POMC LEP INS GNRH1
8 growth hormone deficiency 32.1 SOX3 HESX1 GH1
9 septooptic dysplasia 32.0 TRH SOX3 PROP1 PRL POU1F1 POMC
10 diabetes insipidus 31.6 PRL POMC INS GH1 CRH
11 isolated growth hormone deficiency, type ii 31.5 PROP1 POU1F1 IGF1 HESX1 GHRH GH1
12 pituitary tumors 31.4 PROP1 PRL POMC IGF1 GH1
13 hypogonadotropic hypogonadism 31.3 SHBG PROP1 PRL LEP INS HESX1
14 secondary adrenal insufficiency 31.3 INS IGFBP3 IGF1
15 hypogonadism 31.1 SHBG PROP1 PRL LEP INS IGF1
16 non-acquired panhypopituitarism 31.1 SOX3 PROP1
17 hypothyroidism, congenital, nongoitrous, 4 31.0 PROP1 PRL POU1F1 POMC GH1
18 isolated growth hormone deficiency type iii 31.0 SOX3 HESX1 GHRH GH1
19 hypoglycemia 31.0 PRL POMC INS IGFBP3 IGF1 GHRH
20 thyroiditis 31.0 TRH PRL INS
21 galactorrhea 30.9 PRL IGF1
22 pituitary hypoplasia 30.9 SOX3 PRL POU1F1 LHX4 LHX3 HESX1
23 mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes 30.9 GHRH GH1
24 hypoparathyroidism 30.9 SOX3 INS IGF1
25 acid-labile subunit deficiency 30.8 IGFBP3 IGF1 GH1
26 gigantism 30.8 PRL GHRH GH1
27 adenoma 30.7 TRH PRL POU1F1 POMC IGF1 GHRH
28 graves disease 1 30.7 TRH SHBG POMC INS
29 pituitary stalk interruption syndrome 30.7 SOX3 PRL POU1F1 LHX4 HESX1 GH1
30 gonadal dysgenesis 30.7 SOX3 SHBG GHRH
31 kallmann syndrome 30.7 SOX3 SHBG PROP1 PRL POU1F1 LHX4
32 slipped capital femoral epiphysis 30.7 IGFBP3 IGF1
33 holoprosencephaly 30.7 SOX3 PROP1 POU1F1 LHX4 LHX3 HESX1
34 pituitary apoplexy 30.6 TRH PRL POMC INS IGF1 GNRH1
35 goiter 30.6 TRH SHBG PRL INS IGF1
36 craniopharyngioma 30.5 TRH PROP1 PRL POU1F1 INS IGF1
37 lipid metabolism disorder 30.5 SHBG LEP INS HSD11B1
38 pituitary adenoma 30.5 TRH PRL POU1F1 POMC IGF1 GNRH1
39 pituitary hormone deficiency, combined, 1 30.5 POU1F1 LHX4 LHX3 HESX1
40 chromophobe adenoma 30.4 TRH PRL POMC GH1
41 acth-secreting pituitary adenoma 30.4 PRL POMC CRH
42 impotence 30.4 SHBG PRL POMC INS GNRH1
43 acth deficiency, isolated 30.4 TRH PROP1 PRL POMC LHX4 LHX3
44 hyperprolactinemia 30.4 TRH SHBG PRL POMC INS IGF1
45 central precocious puberty 30.3 IGF1 GNRH1 GH1
46 pituitary gland disease 30.3 TRH SOX3 PROP1 PRL POU1F1 POMC
47 sleep apnea 30.3 LEP INS IGF1
48 insulin-like growth factor i 30.3 SHBG PRL LEP INS IGFBP3 IGF1
49 aromatase deficiency 30.3 INS GNRH1 GH1
50 pseudohypoparathyroidism 30.3 TRH PRL LEP IGF1

Graphical network of the top 20 diseases related to Hypopituitarism:



Diseases related to Hypopituitarism
Sources

Symptoms & Phenotypes for Hypopituitarism

About this section

GenomeRNAi Phenotypes related to Hypopituitarism according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.4 GLI2
2 Decreased viability GR00221-A-2 9.4 GLI2
3 Decreased viability GR00249-S 9.4 GH1 IGFBP3
4 Decreased viability GR00386-A-1 9.4 GLI2 HESX1 LHX3 POMC TRH
5 Decreased viability GR00402-S-2 9.4 GHRH IGFBP3 PROP1

MGI Mouse Phenotypes related to Hypopituitarism:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.43 CRH GHRH GLI2 GNRH1 HESX1 HSD11B1
2 growth/size/body region MP:0005378 10.36 CRH GHRH GLI2 GNRH1 HESX1 HSD11B1
3 homeostasis/metabolism MP:0005376 10.36 CRH GHRH GLI2 GNRH1 HSD11B1 IGF1
4 behavior/neurological MP:0005386 10.29 CRH GHRH GLI2 HSD11B1 IGFBP3 INS
5 nervous system MP:0003631 10.28 CRH GHRH GLI2 GNRH1 HESX1 HSD11B1
6 cellular MP:0005384 10.24 CRH GLI2 HSD11B1 IGF1 IGFBP3 INS
7 adipose tissue MP:0005375 10.13 CRH GHRH HSD11B1 IGF1 IGFBP3 INS
8 integument MP:0010771 10.1 CRH GLI2 GNRH1 HSD11B1 IGF1 IGFBP3
9 liver/biliary system MP:0005370 10.02 CRH GHRH GNRH1 HSD11B1 IGFBP3 INS
10 reproductive system MP:0005389 9.9 GHRH GLI2 GNRH1 IGF1 INS LEP
11 renal/urinary system MP:0005367 9.8 CRH GNRH1 IGF1 INS LEP POMC
12 respiratory system MP:0005388 9.56 CRH GLI2 HESX1 HSD11B1 IGF1 LEP
13 skeleton MP:0005390 9.36 CRH GHRH GLI2 GNRH1 IGF1 IGFBP3
Sources

Drugs & Therapeutics for Hypopituitarism

About this section

Drugs for Hypopituitarism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
2
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
3
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
4
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
5
Racepinephrine Approved Phase 4 329-65-7 838
6
Cosyntropin Approved Phase 4 16960-16-0 16129617
7
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
8 Anti-Inflammatory Agents Phase 4
9 Hormone Antagonists Phase 4
10 Androgens Phase 4
11 Hydrocortisone 17-butyrate 21-propionate Phase 4
12 Hydrocortisone hemisuccinate Phase 4
13 Epinephryl borate Phase 4
14 Vitamins Phase 4
15
Anastrozole Approved, Investigational Phase 2, Phase 3 120511-73-1 2187
16 Antineoplastic Agents, Hormonal Phase 2, Phase 3
17 Estrogens Phase 2, Phase 3
18 Estrogen Antagonists Phase 2, Phase 3
19 Aromatase Inhibitors Phase 2, Phase 3
20 Estrogen Receptor Antagonists Phase 2, Phase 3
21 Edotreotide Phase 3
22 Radiopharmaceuticals Phase 3
23
Testosterone enanthate Approved Phase 2 315-37-7 9416
24
Testosterone undecanoate Approved, Investigational Phase 2 5949-44-0
25
Methyltestosterone Approved Phase 2 58-18-4 6010
26
Pembrolizumab Approved Phase 2 1374853-91-4
27
Cysteamine Approved, Investigational Phase 1, Phase 2 60-23-1 6058
28
Atorvastatin Approved Phase 2 134523-00-5 60823
29 Testosterone 17 beta-cypionate Phase 2
30 Anabolic Agents Phase 2
31 Analgesics Phase 2
32 Antineoplastic Agents, Immunological Phase 2
33 Immunotoxins Phase 2
34 Hypolipidemic Agents Phase 2
35 Lipid Regulating Agents Phase 2
36 Antimetabolites Phase 2
37 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
38 Neuroprotective Agents Phase 2
39 Anticholesteremic Agents Phase 2
40 Growth Hormone-Releasing Hormone Phase 1
41
Estradiol Approved, Investigational, Vet_approved Early Phase 1 50-28-2 5757
42
Pioglitazone Approved, Investigational Early Phase 1 111025-46-8 4829
43
Estrone Approved Early Phase 1 53-16-7 5870
44
Polyestradiol phosphate Approved Early Phase 1 28014-46-2
45
Aspirin Approved, Vet_approved Early Phase 1 50-78-2 2244
46 Acipimox Approved, Investigational 51037-30-0
47
tannic acid Approved 1401-55-4
48
Benzocaine Approved, Investigational 94-09-7, 1994-09-7 2337
49
Dopamine Approved 51-61-6, 62-31-7 681
50
Melatonin Approved, Nutraceutical, Vet_approved Early Phase 1 73-31-4 896

Interventional clinical trials:

(show top 50) (show all 69)
# Name Status NCT ID Phase Drugs
1 Optimising Steroid Replacement in Patients With Adrenal Insufficiency Unknown status NCT03282487 Phase 4 Modified release hydrocortisone
2 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Recombinant human growth hormone
3 Comparison of an Incremental Weight-Based Dose Regimen With an Individualized Dosage Adjusted According to the IGF-I Response in Adults With Growth Hormone Deficiency Completed NCT00490191 Phase 4 Somatropin
4 Physiologic Testosterone Replacement in Women With Hypopituitarism Completed NCT00144391 Phase 4 Transdermal Testosterone gel
5 A Randomised, Controlled, Crossover Study: Treatment With Thyroxin Compared to Thyroxin + Triiodothyronin in Patients With Secondary Hypothyroidism Completed NCT00360074 Phase 4 Thyroxin, Triiodothyronine
6 Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia Completed NCT00140413 Phase 4 Nutropin AQ
7 Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test Completed NCT00851942 Phase 4 Synacthen (Tetracosactrin)
8 Low Dose Euthyrox in Treatments of Paraquat Intoxication: a Randomized, Controlled, Multicenter Trial in China. Not yet recruiting NCT04132622 Phase 4 Levothyroxine Sodium;Traditional therapy
9 Double-blind Trial Investigating the Safety and Efficacy of the Inhibitor Anastrozole (ARIMIDEX) in Delaying Epiphyseal Fusion and Increasing Height Potential of Adolescent Males With Growth Hormone (GH) Deficiency Completed NCT00133354 Phase 2, Phase 3 Arimidex (Anastrozole);Placebo;Growth Hormone
10 Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults Completed NCT01007071 Phase 3 Human Growth Hormone (1-134);Placebo
11 A Phase 3 Open-label Study of Infacort® in Neonates, Infants and Children Less Than 6 Years of Age With Adrenal Insufficiency Completed NCT02720952 Phase 3 Infacort®
12 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
13 Evaluation of Repeated Whole Brain Radiotherapy Versus Best Supportive Care for Multiple Brain Metastases - the Randomized Trial ERASER. Unknown status NCT03288272 Phase 2
14 Will Testosterone and Growth Hormone Improve Bone Structure? Completed NCT00080483 Phase 2 Testosterone plus somatropin;testosterone
15 Interventional Study of Growth Hormone Replacement Therapy in Retired Professional Football Players With Growth Hormone Deficiency Recruiting NCT04121780 Phase 2
16 Supportive Care With or Without Repeated Whole Brain Radiotherapy in Patients With Recurrent Brain Metastases Unsuitable for Resection or Stereotactic Radiotherapy. Recruiting NCT04084431 Phase 2
17 Phase II Study of the Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma Recruiting NCT03644550 Phase 2 LMB-100
18 TTI-0102, a Cysteamine Precursor for Mild to Moderate TBI: Dosing and Feasibility Study Not yet recruiting NCT04262895 Phase 1, Phase 2 TTI-0102;Placebo
19 The Mission Connect Mild TBI Translational Research Consortium's Integrated Clinical Protocol Terminated NCT01013870 Phase 2 Atorvastatin;Placebo
20 Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma Withdrawn NCT01203618 Phase 2 Farletuzumab
21 A Blinded Placebo Controlled Single Ascending Dose Phase 1 for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Subcutaneous Administration of VRS-317 in Adults With Growth Hormone Deficiency Completed NCT01359488 Phase 1 VRS-317;VRS-317;VRS-317;VRS-317;VRS-317
22 Prevalence of Hypopituitarism Following Combat-related Traumatic Brain Injury in a Military Population Unknown status NCT01666964
23 Prospective Longitudinal Study on Pituitary Functions After TBI and/or SAH Unknown status NCT00507104
24 Long Term Follow-up of Moderate and Severe Traumatic Bain Injury and Assessment of Involvement of Hormonal Deficiency in the Quality of Life Unknown status NCT01512524
25 Variability of Uterine and Breast Development in Response to Exogenous Oestrogen During Induction of Puberty in Individuals With Hypogonadism. Unknown status NCT02871986 Routine transdermal oestrogen patch
26 Central Hypothyroidism,a New Laboratory Approach for Hormone Measurement Unknown status NCT01280292 Eltroxin
27 Efficacy of Pulsatile GnRH Therapy on Male Patients With Pituitary Stalk Interruption Syndrome Unknown status NCT02705014 Gonadotropin-releasing Hormone
28 CARDIOVASCULAR RISK FACTORS IN ADULT PATIENTS WITH MULTISYSTEM LANGERHANS-CELL HISTIOCYTOSIS: EVIDENCE OF GLUCOSE METABOLISM ABNORMALITIES Unknown status NCT00483925
29 Identification and Treatment of Biological Clock Dysfunction in Optic Nerve Hypoplasia Unknown status NCT00825591 Early Phase 1
30 Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage Unknown status NCT02915380
31 Central Hypothyroidism and Cardiovascular Risk Factors Completed NCT01574859
32 Posttraumatic Hypopituitarism - Incidence, Predictors and Test Validity Completed NCT01028742
33 Effects of Acute Ghrelin Infusion to Growth Hormone Deficient Adults: Growth Hormone and Cortisol Interaction Completed NCT00139945 Human acylated ghrelin
34 Effects of CRH on the Sleep in Patients With Hypopituitarism Completed NCT00666068
35 TheraDerm Administration in Women With Hypopituitarism Completed NCT00027430 TheraDerm
36 Oestrogen Withdrawal in Hypopituitary Women Completed NCT00572390 oestrogen
37 Hypopituitarism Following Traumatic Brain Injury or Spontaneous Subarachnoidal Haemorrhages Completed NCT00435006
38 Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States Completed NCT00461240
39 Endocrine and Neuropsychological Changes After Aneurismal Subarachnoid Hemorrhage. Completed NCT00962559
40 The Global Hypopituitary Control and Complications Study Completed NCT01088399 Somatropin (rDNA origin)
41 Mediators of Abnormal Reproductive Function in Obesity Completed NCT01817400 Early Phase 1 Aspirin;Pioglitazone
42 Phase 4 Study of Recombinant GH on Intima-Media Thickness at Common Carotids and on Cardiovascular Risk Factors in Hypopituitary Patients Completed NCT00462475 Recombinant Growth Hormone, Genotropin (Pfizer)
43 Registry of Patients Being Treated With Norditropin®, Recombinant Human Growth Hormone Completed NCT01009905 somatropin
44 Lipolytic Effects of GH in Hypopituitary Patients in Vivo: Molecular Mechanisms and Temporal Patterns. Completed NCT02782208 Acipimox;Placebo;GH substitution
45 25-Hydroxyvitamin D Levels Are Negatively Associated With Platelets Number in a Cohort of Overweight and Obese Subjects Completed NCT04133441
46 Effect of Body Composition on Thyroid Hormone Levels Among Overweight and Obese Subjects Completed NCT04327375
47 Relationship Between Skeletal Muscle Mass and Interventricular Septum Thickness in Apparently Healthy Overweight and Obese Subjects Completed NCT04264091
48 24-hour Urinary Aldosterone And Endocrine System In Obesity Completed NCT04354285
49 Metabolic Studies- Interactions Between GH and Insulin in GHDA. Insulin Resistance and GH Treatment: Dependence of Ambient GH Level Among Patients Treated With GH and Healthy Control Subjects Completed NCT00568568 Growth hormone
50 Endotoxin & Cytokines. Do Protein Loss and Metabolic Effects Depend on CNS Activation of Stress Hormones or on Local Mechanisms in Muscle and Fat? Completed NCT01452958

Search NIH Clinical Center for Hypopituitarism

Cochrane evidence based reviews: hypopituitarism

Sources

Genetic Tests for Hypopituitarism

About this section
Sources

Anatomical Context for Hypopituitarism

About this section

MalaCards organs/tissues related to Hypopituitarism:

40
Pituitary, Brain, Thyroid, Testes, Bone, Hypothalamus, Liver
Sources

Publications for Hypopituitarism

About this section

Articles related to Hypopituitarism:

(show top 50) (show all 5074)
# Title Authors PMID Year
1
Comparison of glucose and lipid metabolism and bone mineralization in patients with growth hormone deficiency with and without long-term growth hormone replacement. 61 54
19800640 2010
2
Heterophilic antibodies may be a cause of falsely low total IGF1 levels. 54 61
19608715 2009
3
Pituitary tumours: pituitary incidentalomas. 61 54
19945030 2009
4
Congenital hypopituitarism: clinico-radiological correlation. 61 54
20020580 2009
5
Lack of regulation of 11beta-hydroxysteroid dehydrogenase type 1 during short-term manipulation of GH in patients with hypopituitarism. 54 61
19549748 2009
6
Age and sex as predictors of biochemical activity in acromegaly: analysis of 1485 patients from the German Acromegaly Register. 61 54
19226273 2009
7
Hyperthyroidism unmasked several years after the medical and radiosurgical treatment of an invasive macroprolactinoma inducing hypopituitarism: a case report. 54 61
19829805 2009
8
Deficiency of growth hormone in an adult man case of idiopathic adrenocorticotropin deficiency. 54 61
19367057 2009
9
Growth without growth hormone and similar dysmorphic features in three patients with sporadic combined pituitary hormone deficiencies. 54 61
19844116 2009
10
Sex steroid replacement for induction of puberty in multiple pituitary hormone deficiency. 54 61
19337185 2009
11
[Diagnosis and treatment of adult growth hormone deficiency (aGHD) resulting from brain injury--role of aGHD]. 54 61
19110756 2008
12
Analysis of mouse models carrying the I26T and R160C substitutions in the transcriptional repressor HESX1 as models for septo-optic dysplasia and hypopituitarism. 61 54
19093031 2008
13
A novel dominant negative mutation of OTX2 associated with combined pituitary hormone deficiency. 61 54
18728160 2008
14
A simple and cost-effective approach to assessment of pituitary adrenocorticotropin and growth hormone reserve: combined use of the overnight metyrapone test and insulin-like growth factor-I standard deviation scores. 54 61
18664544 2008
15
Update on epidemiology, etiology, and diagnosis of adult growth hormone deficiency. 54 61
19020378 2008
16
Diagnostic usefulness of the growth hormone-releasing peptide-2 test as a substitute for the insulin tolerance test in hypopituitarism. 61 54
18493103 2008
17
Heterozygous mutation of HESX1 causing hypopituitarism and multiple anatomical malformations without features of septo-optic dysplasia. 61 54
18852528 2008
18
Novel mutations in LHX3 are associated with hypopituitarism and sensorineural hearing loss. 61 54
18407919 2008
19
Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours. 61 54
18031317 2008
20
Diagnosis of adult GH deficiency. 54 61
17766155 2008
21
[Problems typical for patients with hypopituitarism - a case presentation]. 54 61
18577349 2008
22
Diagnosis of adult GH deficiency. 54 61
18404387 2008
23
An audit of treatment outcome in acromegalic patients attending our center at Bergamo, Italy. 54 61
17690987 2008
24
Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism. 54 61
18057377 2007
25
Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. 54 61
18057375 2007
26
Molecular analysis of PROP1, PIT1, HESX1, LHX3, and LHX4 shows high frequency of PROP1 mutations in patients with familial forms of combined pituitary hormone deficiency. 61 54
18157385 2007
27
Effects of testosterone therapy on cardiovascular risk markers in androgen-deficient women with hypopituitarism. 54 61
17426086 2007
28
Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. 61 54
19669352 2007
29
[Arterial stiffness in hypopituitary patients with life-long growth hormone deficiency]. 54 61
18030871 2007
30
GH response to ghrelin in subjects with congenital GH deficiency: evidence that ghrelin action requires hypothalamic-pituitary connections. 61 54
17389459 2007
31
Acquired prolactin deficiency in patients with disorders of the hypothalamic-pituitary axis. 61 54
17556861 2007
32
HESX1 mutations are an uncommon cause of septooptic dysplasia and hypopituitarism. 61 54
17148560 2007
33
Polyalanine expansion mutations in the X-linked hypopituitarism gene SOX3 result in aggresome formation and impaired transactivation. 54 61
17127446 2007
34
Hormonal, pituitary magnetic resonance, LHX4 and HESX1 evaluation in patients with hypopituitarism and ectopic posterior pituitary lobe. 61 54
17201807 2007
35
Growth hormone levels in the diagnosis of growth hormone deficiency in adulthood. 54 61
17429591 2007
36
Hypopituitarism oddities: congenital causes. 61 54
18174732 2007
37
Effect of thyroxine replacement on serum IGF-I, IGFBP-3 and the acid-labile subunit in patients with hypothyroidism and hypopituitarism. 54 61
17121519 2006
38
Hypopituitarism in childhood and adolescence following traumatic brain injury: the case for prospective endocrine investigation. 61 54
17062881 2006
39
PROP1 gene analysis in Portuguese patients with combined pituitary hormone deficiency. 54 61
16984240 2006
40
Serum ghrelin levels are suppressed in hypopituitary patients following insulin-induced hypoglycaemia irrespective of GH status. 61 54
16886962 2006
41
A case of catecholamine and glucocorticoid excess syndrome due to a corticotropin-secreting paraganglioma. 61 54
17102072 2006
42
Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. 61 54
16403824 2006
43
Clinical case seminar: a novel LHX3 mutation presenting as combined pituitary hormonal deficiency. 61 54
16394081 2006
44
Hypopituitarism. 54 61
17077946 2006
45
[Standardization of DNA extraction with NaCl from oral mucosa cells: application in PROP1 gene study]. 54 61
16544023 2005
46
Hypothalamic-pituitary dysfunction after irradiation of nonpituitary brain tumors in adults. 61 54
16144946 2005
47
Duplication of Xq26.2-q27.1, including SOX3, in a mother and daughter with short stature and dyslalia. 61 54
16097007 2005
48
Mutations within the transcription factor PROP1 are rare in a cohort of patients with sporadic combined pituitary hormone deficiency (CPHD). 54 61
15963055 2005
49
[Primary hypothyroidism associated with empty sella turcica and hypopituitarism]. 61 54
16296587 2005
50
Different degrees of GH deficiency evidenced by GHRH+arginine test and IGF-I levels in adults with pituritary disease. 54 61
15952410 2005
Sources

Variations for Hypopituitarism

About this section
Sources

Expression for Hypopituitarism

About this section
Search GEO for disease gene expression data for Hypopituitarism.
Sources

Pathways for Hypopituitarism

About this section

Pathways related to Hypopituitarism according to KEGG:

36
# Name Kegg Source Accession
1 Neuroactive ligand-receptor interaction hsa04080

Pathways related to Hypopituitarism according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 65
Show member pathways
 13.36 TRH PRL POMC LEP GNRH1 GHRH
2
Prolactin Signaling Pathway 36 1
Show member pathways
 12.25 PRL LEP INS GH1
3
Relaxin signaling pathway 36
Show member pathways
 12.23 POU1F1 POMC IGFBP3 IGF1 GHRH GH1
4
Adipogenesis 1
11.79 LEP INS IGF1 GH1
5
Senescence and Autophagy in Cancer 1
11.71 INS IGFBP3 IGF1
6
Peptide hormone metabolism 65
Show member pathways
 11.61 POMC LEP INS IGF1 GH1
7
Glucocorticoid receptor regulatory network 1
11.55 PRL POU1F1 POMC
8
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.54 LEP INS IGFBP3 IGF1
9
Signaling events mediated by PTP1B 1
11.28 PRL LEP INS
10
Development_Leptin signaling via JAK/STAT and MAPK cascades 22
Show member pathways
 10.97 TRH POMC LEP
11
Glucocorticoid Pathway (HPA Axis), Pharmacodynamics 60
10.28 POMC CRH
12
Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics 60
10.23 PRL POMC LEP INS
Sources

GO Terms for Hypopituitarism

About this section

Cellular components related to Hypopituitarism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 9.85 SOX3 PROP1 POU1F1 LHX4 LHX3 HESX1
2 extracellular space GO:0005615 9.85 PRL POMC LEP INS IGFBP3 IGF1
3 extracellular region GO:0005576 9.4 TRH SHBG PRL POMC LEP INS
4 insulin-like growth factor ternary complex GO:0042567 9.32 IGFBP3 IGF1
5 insulin-like growth factor binding protein complex GO:0016942 9.26 IGFBP3 IGF1
6 endosome lumen GO:0031904 9.13 PRL INS GH1

Biological processes related to Hypopituitarism according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.24 TRH PRL POMC LEP INS IGF1
2 negative regulation of transcription by RNA polymerase II GO:0000122 10.1 SOX3 PROP1 POU1F1 LEP HESX1 GLI2
3 positive regulation of transcription by RNA polymerase II GO:0045944 10.1 SOX3 PROP1 POU1F1 POMC LHX4 LHX3
4 cellular protein metabolic process GO:0044267 9.92 PRL INS IGFBP3 IGF1
5 negative regulation of apoptotic process GO:0043066 9.87 PROP1 LHX4 LHX3 LEP IGF1 GNRH1
6 cell-cell signaling GO:0007267 9.85 TRH POMC INS GNRH1 GHRH
7 positive regulation of MAPK cascade GO:0043410 9.83 LEP INS IGFBP3 IGF1
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.79 LEP IGF1 GH1
9 response to nutrient levels GO:0031667 9.77 PRL LEP GH1
10 positive regulation of cell proliferation GO:0008284 9.76 PRL POU1F1 LEP INS IGF1 GLI2
11 placenta development GO:0001890 9.75 LHX4 LHX3 LEP
12 dorsal/ventral pattern formation GO:0009953 9.74 PROP1 LHX3 GLI2
13 lung development GO:0030324 9.73 LHX3 HSD11B1 GLI2 CRH
14 positive regulation of multicellular organism growth GO:0040018 9.71 POU1F1 GHRH GH1
15 female pregnancy GO:0007565 9.71 PRL LEP GNRH1 CRH
16 positive regulation of JAK-STAT cascade GO:0046427 9.69 PRL LEP GH1
17 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.67 LEP INS IGF1 GH1
18 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.64 PRL GH1
19 hypothalamus development GO:0021854 9.63 SOX3 CRH
20 glucocorticoid biosynthetic process GO:0006704 9.62 HSD11B1 CRH
21 regulation of insulin-like growth factor receptor signaling pathway GO:0043567 9.61 POU1F1 IGFBP3
22 bone mineralization involved in bone maturation GO:0035630 9.59 LEP IGF1
23 negative regulation of glucagon secretion GO:0070093 9.56 LEP CRH
24 somatotropin secreting cell differentiation GO:0060126 9.55 PROP1 POU1F1
25 medial motor column neuron differentiation GO:0021526 9.48 LHX4 LHX3
26 adenohypophysis development GO:0021984 9.43 PROP1 POU1F1 GHRH
27 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.26 IGFBP3 IGF1 GHRH GH1
28 pituitary gland development GO:0021983 9.1 SOX3 PROP1 POU1F1 LHX3 HESX1 GLI2

Molecular functions related to Hypopituitarism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.73 PROP1 POU1F1 LHX4 LHX3 HESX1 GLI2
2 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.72 PROP1 POU1F1 LHX4 LHX3 GLI2
3 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.7 SOX3 PROP1 POU1F1 LHX4 LHX3 HESX1
4 insulin-like growth factor receptor binding GO:0005159 9.4 INS IGF1
5 peptide hormone receptor binding GO:0051428 9.37 LEP GHRH
6 hormone activity GO:0005179 9.32 TRH PRL POMC LEP INS IGF1
7 prolactin receptor binding GO:0005148 8.96 PRL GH1
Sources

Sources for Hypopituitarism

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....